Previous 10 | Next 10 |
ABEV,ACIW,ACRS,AEP,AGIO,AHCO,ALIM,AMT,ATHM,OTCQX:AXAHY,AZUL,BABA,BLI,BUD,CARS,CBRE,CCO,CCOI,OTCPK:CDUAF,CGEN,CLDT,CMPS,CWT,CYD,DAO,DBRG,OTCPK:DDAIF,DEN,DISCA,DISH,DOCN,OTCQX:DTEGY,EDIT,ELAN,EME,EXPI,FOLD,GCI,GLNG,GNK,GNL,GTLS,HMHC,HYLN,IBP,IMUX,IONS,IRM,ISEE,KDP,KRP,OTCPK:LBLCF,LNG,LNTH,LXP,L...
IVERIC bio, Inc. (Nasdaq: ISEE) today announced that it will report its fourth quarter and full year 2021 financial and operating results on Thursday, February 24, 2022. Following the announcement, the Iveric Bio management team will host a live conference call and webcast at 8:00 a...
- Analysis Further Highlights the Potential for Zimura to Slow the Progression of Disease and Preserve Foveal Anatomy while Sparing the Foveal Center in Patients with GA - IVERIC bio, Inc. (Nasdaq: ISEE) announced today a post-hoc analysis which evaluated various Geograp...
IVERIC bio (NASDAQ:ISEE) is poised to open higher on Monday after Morgan Stanley initiated its coverage with an Overweight recommendation citing the potential of the company’s geographic atrophy candidate, Zimura ahead of a pivotal data readout. Announcing its Q3 2021 results in Novemb...
IVERIC Bio, Inc. (Nasdaq: ISEE) announced today that new post-hoc analyses from the GATHER1 Zimura ® (avacincaptad pegol) Phase 3 clinical trial for the treatment of Geographic Atrophy (GA) secondary to Age-related Macular Degeneration will be presented at the upcoming Angi...
IVERIC Bio (NASDAQ:ISEE) granted an equity-based award to a newly hired non-executive employee; consists of non-statutory stock option to purchase 14K shares. The stock options each have an exercise price of $14.43/share, equivalent to Feb.1 closing price, and has a 10-year term and vests ove...
- Extensive Track Record in U.S. and Global Product Launches and Supply Chain Management - IVERIC bio, Inc. (Nasdaq: ISEE) announced today the election of Christine Ann Miller to its Board of Directors, effective immediately. A global pharmaceutical veteran with more tha...
IVERIC bio, Inc. (Nasdaq: ISEE) announced today that Pravin U. Dugel, M.D., President, will present an overview of the Company at the H.C. Wainwright BioConnect Virtual Conference, being held virtually from January 10-13, 2022. The on-demand presentation will be available for vi...
– Highly-Recognized Operational Executive and Strategic Advisor to Biotechnology Companies with a Proven Track Record – IVERIC bio, Inc. (Nasdaq: ISEE) announced today the appointment of Tony Gibney to Executive Vice President and Chief Business and Str...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips While this isn’t the end of giant pharmaceutical companies, there is a new generation of biotechs that have been able to advance rapidly due to the massive advances in computer technology in recent decades. These A-r...
News, Short Squeeze, Breakout and More Instantly...
Astellas Completes Acquisition of Iveric Bio PR Newswire TOKYO and PARSIPPANY, N.J. , July 11, 2023 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura , "Astellas") today announced that it has successfully completed the acquisit...
Shares of IVERIC bio, Inc. (NASDAQ: ISEE) traded at a new 52-week high today and are currently trading at $39.73. So far today, approximately 1.78M shares have been exchanged, as compared to an average 30-day volume of 5.04M shares. IVERIC bio, Inc., a biopharmaceutical company, discovers and...
IVERIC bio, Inc. (NASDAQ: ISEE) has caught the attention of the investment community today with its bullish price action. The company's shares are currently up 1.93% on the day to $38.77. IVERIC bio, Inc., a biopharmaceutical company, discovers and develops novel treatments for retinal disease...